Benzinga | Jan 7, 2022 01:02PM EST

Piper Sandler Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $171

Piper Sandler initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $171.